A peptide antagonist of melanocortin receptors
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

TCMCB07 (trifluoroacetate salt)

Item No. 41545

Technical Information
Formal Name
N-acetyl-L-norleucyl-L-α-aspartyl-L-prolyl-3-(2-naphthalenyl)-D-alanyl-L-arginyl-L-tryptophyl-L-lysyl-D-valyl-D-prolinamide, (2→7)-lactam, trifluoroacetate salt
Synonyms
  • Ac-Nle-Asp-Pro-D-2Nal-Arg-Trp-Lys-D-Val-D-Pro-NH2
  • Mifomelatide
Molecular Formula
C63H87N15O11 • XCF3COOH
Formula Weight
Purity
≥98%
A solid
Peptide Sequence
Ac-XDPzRWKvp-NH2 (X = norisoleucine; z = 3-(2-naphalyl)-D-alanine)
DMSO: Soluble: ≥10 mg/mlEthanol: Soluble: ≥10 mg/ml
SMILES
O=C([C@@H](NC([C@H](NC([C@@]1([H])N(CCC1)C([C@H](CC(NCCCC[C@H](NC2=O)C(N[C@H](C(C)C)C(N3[C@H](CCC3)C(N)=O)=O)=O)=O)NC([C@H](CCCC)NC(C)=O)=O)=O)=O)CC4=CC5=C(C=CC=C5)C=C4)=O)CCCNC(N)=N)N[C@H]2CC6=CNC7=CC=CC=C67.OC(C(F)(F)F)=O
InChi Code
InChI=1S/C63H87N15O11.C2HF3O2/c1-5-6-19-44(70-37(4)79)55(82)75-49-34-52(80)67-27-12-11-21-45(57(84)76-53(36(2)3)62(89)77-29-14-23-50(77)54(64)81)71-59(86)48(33-41-35-69-43-20-10-9-18-42(41)43)73-56(83)46(22-13-28-68-63(65)66)72-58(85)47(74-60(87)51-24-15-30-78(51)61(49)88)32-38-25-26-39-16-7-8-17-40(39)31-38;3-2(4,5)1(6)7/h7-10,16-18,20,25-26,31,35-36,44-51,53,69H,5-6,11-15,19,21-24,27-30,32-34H2,1-4H3,(H2,64,81)(H,67,80)(H,70,79)(H,71,86)(H,72,85)(H,73,83)(H,74,87)(H,75,82)(H,76,84)(H4,65,66,68);(H,6,7)/t44-,45-,46-,47+,48-,49-,50+,51-,53+;/m0./s1
InChi Key
MSNXMNKRZUHQHJ-PNSCJSEPSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    TCMCB07 is a peptide antagonist of melanocortin receptor 1 (MC1R), MC3R, MC4R, and MC5R (IC50s = 19.5, 0.59, 13.58, and 8.07 nM, respectively, for the human receptors).1 It is also an antagonist of dog MC1R, MC3R, MC4R, and MC5R receptors (IC50s = 53.64, 1.46, 7.14, and 11.22 nM, respectively). TCMCB07 (10 mg/kg) increases food intake and body weight in a rat model of LPS-induced cachexia. It increases body weight, muscle mass, blood levels of urea nitrogen, and mean heart rate in dogs with cachexia when administered at a dose of 0.75 mg/kg per day.2

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Gruber, K.A., Ji, R.L., Gallazzi, F., et alDevelopment of a therapeutic peptide for cachexia suggests a platform approach for drug-like peptides. ACS Pharmacol. Transl. Sci. 5(5), 344-361 (2022).

    2. Axiak-Bechtel, S.M., Leach, S.B., Newton-Northup, J.R., et alSafety of TCMCB07, a melanocortin-4 antagonist peptide, in dogs with naturally occurring cachexia. J. Vet. Intern. Med. 37(6), 2344-2355 (2023).